CD-GA-102
Phase 1Small molecule
CD-GA-102 is one of 29 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
698 competitors in Metastatic Colorectal Cancer
#DrugCompanyPhaseTrials
1Vectibix
AmgenPhase 3
Braftovi
PfizerPhase 3
Theraplaza
BBiotech Pharmaceutical Co., Ltd.
Phase 3
Cosela
PPharmacosmos A/S
Phase 3
Fusilev
DDurata Therapeutics International BV (an Affiliate of Actavis, Inc.)
Phase 3
Vatalanib
NovartisPhase 3
PF-08634404
PfizerPhase 3
Investigator's Choice Chemotherapy
GenmabPhase 3
Brivanib Alaninate
GGynecologic Oncology Group
Phase 3
FOLFOX 2d
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CD-GA-102. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- SShanghai Changzheng Hospital